You just read:

Celator Announces Phase 3 Trial for VYXEOS™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival

News provided by

Celator Pharmaceuticals, Inc.

Mar 14, 2016, 04:01 ET